Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changchun Haiyue Pharmaceutical
Changchun, Jilin Sheng, Chinahaiyue.net.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Changchun Haiyue Pharmaceutical has commercialized at least one drug—esomeprazole magnesium/sodium bicarbonate—for duodenal ulcer in China since September 2022. The company also develops or licenses drugs targeting proton pumps and PPARα, with some products approved outside China via partnerships. Its pipeline includes several small molecule drugs across digestive, metabolic, oncology, infectious disease, and ENT indications.
- Therapeutic areas
- Infectious DiseasesGastroenterologyEndocrinologyOncologyOtherCardiovascular
- Modalities
- Small moleculeProton pump inhibitor (as a class of small molecules)PPARα agonist (as a class of small molecules)
- Industry
- Biotech
02
Partnerships
Hanmi Pharmaceutical Co., Ltd. for fenofibric acid licensing/distribution
Beyond the preview
Go deeper on Changchun Haiyue Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changchun Haiyue Pharmaceutical.